Arrowhead Pharmaceuticals
Open
$72.14
Prev. Close
$72.10
High
$72.14
Low
$72.14
Market Snapshot
$9.58B
47.4
-5.16
$2.5M
711
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 711 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
emptyResult
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 711 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Recently from Cashu
Arrowhead Pharmaceuticals Pioneers Gene Editing Innovations in RNA-targeted Therapeutics
Arrowhead Pharmaceuticals Advances Gene Editing Innovations Arrowhead Pharmaceuticals is at the forefront of revolutionizing medical treatment through its innovative approaches in RNA-targeted therape…
Arrowhead Pharmaceuticals Advances Obesity Treatment with Promising RNAi Clinical Trial Results
Arrowhead Pharmaceuticals Makes Strides in Obesity Treatment with Promising Clinical Trial Results Arrowhead Pharmaceuticals is making significant advancements in the field of obesity treatment, as in…
Arrowhead Pharmaceuticals: Thriving Amid Market Challenges and Economic Uncertainty
Arrowhead Pharmaceuticals Navigates Market Challenges Amid Broader Economic Concerns Arrowhead Pharmaceuticals faces a complex economic landscape as market downturns continue to shape investor sentime…
Arrowhead Pharmaceuticals (ARWR) Sees Stock Surge Amid Strong Financial Results and Strategic Execution
Arrowhead Pharmaceuticals: A Surge in Performance Reflecting Strong Strategic Execution Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reveals a significant uptick in its stock value following the rel…